Drug Trial Radar · NCT06522997
A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,222
Actual
Start
Aug 8, 2024
Primary completion
Oct 24, 2025
Study completion Nov 20, 2025
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Jul 26, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD), CKD is a condition in which the kidneys' ability to work properly gradually decreases over time. A common sign of decreasing kidney function is the body losing too much of a protein called albumin in the urine. This condition is known as albuminuria. This can lead to a faster decline in kidney function. People who have high blood pressure and diabetes are more likely to have CKD and are at a higher risk of complications related to it. BAY3283142 is a new drug that is being developed to treat people with CKD. It works by activating a protein that helps relax blood vessels and is thought to have beneficial effects in CKD. In this study, researchers want to learn about how well different doses of BAY3283142 work when taken with standard treatment for CKD in reducing albumin in the urine of participants with CKD. They will compare the results of the change in the urine albumin-creatinine ratio (UACR) after 16 weeks for BAY3283142 with a placebo. A placebo looks like the study drug but does not have any medicine in it. During the study, participants will take either of the following drugs: * BAY3283142: Participants will take BAY3283142 as tablets by mouth. * Placebo: Participants will take it in the same way as BAY3283142. Participants will continue taking the available standard treatment for CKD and other conditions they may have (for example, heart conditions and diabetes). At the start of this study, the researchers will check the medical history and current medications of the participants. They will also perform a complete health check-up of all the participants. Researchers will take urine and blood samples from the participants at different time points to measure UACR and eGFR. Participants will be divided equally into different groups. Only 1 group will receive placebo and the other groups will receive BAY3283142. Participants will take their assigned treatment for 16 weeks. No one will know who receives which drug or dose of BAY3283142 during the study. Participants will be in this study for around 23 weeks. This includes the time for screening before the start of treatment and follow-up with participants after treatment. People can join this study if they: * are 18 years of age or older and have been diagnosed with CKD * have poor kidney function according to the eGFR test * have abnormally high levels of albumin in the urine according to the UACR test * have been taking certain drugs at a stable dose for management of high blood pressure, diabetes, kidney disease, etc. for at least 4 weeks before the start of the study People cannot join this study if they: * have low blood pressure * have had a stroke or a heart attack, or were hospitalized because of heart failure in the 3 months before the start of the study * have a serious liver disease * have a kidney disease for which they need to take drugs that control the immune system The detailed requirements will be discussed between the study doctors and people considering joining this study. Participants may or may not get the expected benefits of treatment with BAY3283142, but they will receive thorough medical check-ups during this study. These can help to improve individual treatment in the future and to identify unknown medical risks. Some participants may experience medical problems during this study including pain and discomfort when blood samples are taken. Researchers will closely monitor and manage any medical problems the participants may have. They will not include people who should not take BAY3283142 due to known safety concerns. The findings from this study may contribute to developing a new treatment option for people with CKD who have excess albumin in the urine.
Conditions
- Chronic Kidney Disease
Interventions
BAY3283142Drug
Tablet, intake orally once daily
PlaceboDrug
Matching with BAY3283142
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to Week 16 in the logarithm of urine albumin-creatinine ratio (UACR)Time frame: From baseline to Week 16
Locations
153 sites in 15 countries. Site status is shown where the registry gives one.
Nephrology Consultants, LLC
Huntsville, Alabama
Balboa Research SMO+ - Chula Vista
Chula Vista, California
California Kidney Specialists - San Dimas
San Dimas, California
Yale Nephrology Clinical Research Clinic
New Haven, Connecticut
Nova Clinical Research - Blake Medical Center
Bradenton, Florida
Renstar Medical Research - Deerwood Clinic
Ocala, Florida
Elixia Central Florida
Orlando, Florida
Florida Institue for Clinical Research
Orlando, Florida
Southeastern Clinical Research Institute, LLC
Augusta, Georgia
Research by Design, LLC | Chicago, IL
Chicago, Illinois
Nephrology Associates of Northern Illinois and Indiana - Hinsdale
Hinsdale, Illinois
Triad Internal Medicine - Asheboro
Asheboro, North Carolina
Eastern Nephrology Associates - New Bern
New Bern, North Carolina
Brookview Hills Research Associates, LLC
Winston-Salem, North Carolina
Knoxville Kidney Center, PLLC
Knoxville, Tennessee
Vanderbilt University Medical Center - Nephrology Clinical Trials Center
Nashville, Tennessee
Renal Disease Research Institute | Landry
Dallas, Texas
Southwest Houston Research, Ltd.
Houston, Texas
Clinical Advancement Center, PLLC
San Antonio, Texas
Utah Kidney Research Institute | Salt Lake City, UT
South Salt Lake, Utah
Peninsula Kidney Associates - Hampton
Hampton, Virginia
Manassas Clinical Research Center
Manassas, Virginia
Salem VA Medical Center - Nephrology
Salem, Virginia
Mendez Center For Clinical Research | Woodbridge, VA
Woodbridge, Virginia
Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC)
Buenos Aires, Argentina
Centro Privado San Vicente Diabetes
Córdoba, Argentina
Fundacion Centro de Salud e Investigaciones Medicas | Santa Rosa, Argentina
Santa Rosa, Argentina
Centro de Investigaciones Metabolicas | Ciudad de Autonoma de Buenos Aires, Argentina
Ciudad Autónoma de Buenos Aire, Buenos Aires, Argentina
Centro de Investigaciones Medicas Temperley | Buenos Aires, Argentina
Temperley, Buenos Aires, Argentina
CEDIC Centro de Investigación Clínica | Buenos Aires, Argentina
CABA, Ciudad Auton. de Buenos Aires, Argentina
Centro de Especialidades Medicas (Cemedic) | Cardiology Department
Villa Luro, Ciudad Auton. de Buenos Aires, Argentina
Centro de Rehabilitacion Cardiovascular | San Luis, Argentina
San Luis, San Luis Province, Argentina
Epicura / Nephrology
Baudour, Belgium
UZ Gent / Nephrology
Ghent, Belgium
Jan Yperman Ziekenhuis / Nephrology
Ieper, Belgium
UZ Brussel Nephrology
Jette, Belgium
UZ Leuven / Nephrology
Leuven, Belgium
AZ Delta / Nephrology
Roeselare, Belgium
Capital Medical University (CMU) - Beijing Anzhen Hospital (BAH)
Beijing, China
Peking University People's Hospital
Beijing, China
Showing 40 of 153 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.